UK markets close in 2 hours 34 minutes

Merck & Co., Inc. (0QAH.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
89.70+0.19 (+0.22%)
As of 06:10PM GMT. Market open.
Full screen
Previous close89.51
Open92.36
Bid0.00 x N/A
Ask0.00 x N/A
Day's range89.12 - 89.48
52-week range84.53 - 119.56
Volume1,080
Avg. volume63,990
Market capN/A
Beta (5Y monthly)0.38
PE ratio (TTM)0.16
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Yahoo Finance Video

    FDA approves Merck treatment for lung disease, potential path to upside

    The Food and Drug Administration has approved Winrevair, Merck's (MRK) latest drug to treat pulmonary arterial hypertension, a lung condition. Investors have been anxiously awaiting the approval as the company is set to lose its patent for Keytruda. The drug will help to reduce the risk of death and worsening events in patients by 84%. Yahoo Finance's Anjalee Khemlani joins The Morning Brief to discuss how the treatment could offer a potential path to the upside for Merck. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. Editor's Note: This article was written by Gabriel Roy

  • Yahoo Finance Video

    Moderna stock pops on launch of skin cancer treatment trial

    Moderna (MRNA) shares are trading higher Monday after the biotechnology company revealed the start of a clinical trial for a skin cancer treatment. Moderna has partnered with the pharmaceutical giant Merck (MRK) to test the drug, in a bid to diversify beyond its core vaccine business. Yahoo Finance's Julie Hyman and Brian Sozzi breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Angel Smith

  • Yahoo Finance

    Moderna CEO: 2024 is year of growth, with 2023 transition in rearview

    Moderna posted strong results despite investors assuming a loss for the year.